评估供者来源 B 细胞输注治疗肌萎缩侧索硬化（ALS）患者
Evaluation of Donor-Derived B Cell Infusions in Patients With Amyotrophic Lateral Sclerosis (ALS)
肌萎缩侧索硬化（ALS，一种导致运动神经元逐渐死亡的神经退行性疾病）目前缺乏有效阻止病情进展的疗法。该1期试验将评估向最多10名ALS患者输注来自相关供者的B细胞（一种免疫细胞）是否安全，受试者间隔至少60天接受两次输注。主要观察副作用、免疫排斥及是否值得进一步研究，前三名受试者将在医院接受输注并加强安全监测。这是该细胞疗法在ALS中的首次人体试验，尚未开始招募。
为什么推荐给您：全新细胞疗法在ALS中的首次人体试验，探索新免疫治疗路径，但仅为1期安全性注册。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Brief summary: This study is testing whether giving people with ALS specially matched immune cells called B cells from a related donor is safe. Up to 10 participants will each receive two B cell infusions at least 60 days apart. The main goals are to watch closely for side effects, see whether the participant's immune system rejects the donor cells, and determine whether this treatment should be studied further in people with ALS. The first three participants will receive the infusions in the hospital with extra safety spacing between participants; if those infusions appear safe, the remaining participants may receive them in an outpatient setting.
Conditions: ALS - Amyotrophic Lateral Sclerosis
Interventions: biological: B cell infusion
Phase: Phase 1
Enrollment: 10 (estimated)
Sponsor: Mark Poznansky (other)
Countries: United States
Status: not yet recruiting